Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v28-FR Version v5-EN
Language French English
Date Updated 2020-09-08 2019-05-10
Drug Identification Number 02368676 02368676
Brand name TRIESENCE TRIESENCE
Common or Proper name TRIESENCE 1ML SUSP X12 TRIESENCE 1ML SUSP X12
Company Name NOVARTIS PHARMACEUTICALS CANADA INC NOVARTIS PHARMACEUTICALS CANADA INC
Ingredients TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE
Strength(s) 40MG 40MG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRAVITREAL INTRAVITREAL
Packaging size 12 12
ATC code S01BA S01BA
ATC description ANTIINFLAMMATORY AGENTS ANTIINFLAMMATORY AGENTS
Reason for shortage Other (Please describe in comments) Delay in shipping of the drug.
Anticipated start date 2019-06-03 2019-06-03
Actual start date 2019-05-27
Estimated end date 2020-08-31 2019-10-08
Actual end date 2020-09-02
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Production constraints limit product availability. Inventory being periodically released based on stock received.
Health Canada comments